Published in Clin Exp Metastasis on January 01, 2005
Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res (2009) 1.49
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res (2007) 1.38
miR451 and AMPK mutual antagonism in glioma cell migration and proliferation: a mathematical model. PLoS One (2011) 0.99
Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. ScientificWorldJournal (2013) 0.97
MSMB variation and prostate cancer risk: clues towards a possible fungal etiology. Prostate (2014) 0.93
Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J Neurosci Res (2008) 0.92
Regulation of cell proliferation and migration in glioblastoma: new therapeutic approach. Front Oncol (2013) 0.89
Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum Mutat (2012) 0.89
Targeting bone physiology for the treatment of metastatic prostate cancer. Clin Adv Hematol Oncol (2013) 0.80
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer. PLoS One (2015) 0.77
Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. J Cereb Blood Flow Metab (2016) 0.77
Purification and preliminary X-ray crystallographic studies of beta-microseminoprotein from human seminal plasma. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.77
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
RHO-GTPases and cancer. Nat Rev Cancer (2002) 8.03
CD44: structure, function, and association with the malignant process. Adv Cancer Res (1997) 3.66
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science (1997) 3.28
Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol (2005) 3.20
Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol (1999) 2.91
CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res (2004) 2.51
Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem (1986) 2.50
Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem (2004) 2.37
Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev (2005) 2.19
CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol (1998) 1.93
Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer (2004) 1.73
Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem (2005) 1.59
Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst (1995) 1.55
Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci U S A (1993) 1.52
CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia (2001) 1.48
Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev (2003) 1.45
Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res (2003) 1.44
Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer (2005) 1.42
Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression. J Cell Sci (2005) 1.34
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol (2005) 1.32
Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res (2003) 1.31
Transmembrane domain of CD44 is required for its detergent insolubility in fibroblasts. J Cell Sci (1995) 1.27
Dynamic process of prostate cancer metastasis to bone. J Cell Biochem (2004) 1.22
Integrin ligation and PKC activation are required for migration of colon carcinoma cells. J Cell Sci (1998) 1.20
HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci (2003) 1.20
CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene (2005) 1.17
Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J (2001) 1.17
RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res (2003) 1.16
Type I collagen in solution. Structure and properties of fibril fragments. J Biol Chem (1980) 1.16
Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence in Local Prostate Cancer. Urol Int (2002) 1.12
Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis (1999) 1.10
Localization of RhoA GTPase to endothelial caveolae-enriched membrane domains. Biochem Biophys Res Commun (1998) 1.08
Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell (1999) 1.07
Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins. J Biol Chem (2000) 1.03
Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. J Biol Chem (1995) 1.01
Cellular interactions in the tropism of prostate cancer to bone. Int J Cancer (2004) 1.00
Proteolyzed matrix as a template for the regulation of tumor progression. Biomed Pharmacother (2003) 0.98
Antibody-induced shedding of CD44 from adherent cells is linked to the assembly of the cytoskeleton. J Immunol (2001) 0.97
Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. J Urol (1998) 0.94
Probing the infiltrating character of brain tumors: inhibition of RhoA/ROK-mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCg. J Neurochem (2005) 0.89
Calcium-induced matrix metalloproteinase 9 gene expression is differentially regulated by ERK1/2 and p38 MAPK in oral keratinocytes and oral squamous cell carcinoma. J Biol Chem (2004) 0.87
Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells. J Biol Chem (2004) 0.86
A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res (2004) 0.84
Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery (1999) 0.84
Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate (1999) 0.82
Detection of PSP94 and its specific binding sites in the prostate adenocarcinoma cell line LNCaP. J Urol (1998) 0.80
Does soluble CD44 reflect the clinical behavior of human cancer? Curr Top Microbiol Immunol (1996) 0.77
Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer (2005) 0.76
Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells. Biochem J (2001) 0.76
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Antimicrobial drug discovery through bacteriophage genomics. Nat Biotechnol (2004) 4.17
Nonhistone Scm3 and histones CenH3-H4 assemble the core of centromere-specific nucleosomes. Cell (2007) 3.55
Use and Impact of eHealth System by Low-income Women With Breast Cancer. J Health Commun (2005) 2.98
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Fast multicolor 3D imaging using aberration-corrected multifocus microscopy. Nat Methods (2012) 2.25
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol (2008) 2.06
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90
Reducing the digital divide for low-income women with breast cancer: a feasibility study of a population-based intervention. J Health Commun (2005) 1.80
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Internet-Based Interactive Support for Cancer Patients: Are Integrated Systems Better? J Commun (2008) 1.72
A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol (2006) 1.71
Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells (2003) 1.70
A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion. Breast Cancer Res (2012) 1.70
Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell (2003) 1.67
Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res (2013) 1.64
DNA methylation and breast cancer. Biochem Pharmacol (2004) 1.57
Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Exp Cell Res (2012) 1.51
Effects of insightful disclosure within computer mediated support groups on women with breast cancer. Health Commun (2006) 1.50
Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J Biol Chem (2007) 1.50
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res (2007) 1.45
A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J Biol Chem (2003) 1.45
Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol (2010) 1.43
Inhibition of sphingosine-1-phosphate- and vascular endothelial growth factor-induced endothelial cell chemotaxis by red grape skin polyphenols correlates with a decrease in early platelet-activating factor synthesis. Free Radic Biol Med (2005) 1.43
Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res (2006) 1.43
Radiation induced-tubulogenesis in endothelial cells is antagonized by the antiangiogenic properties of green tea polyphenol (-) epigallocatechin-3-gallate. Cancer Biol Ther (2003) 1.42
Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from biological membranes. Biochem J (2002) 1.42
Relevance of CONSORT reporting criteria for research on eHealth interventions. Patient Educ Couns (2010) 1.40
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem (2004) 1.36
Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res (2009) 1.36
Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer (2010) 1.35
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer (2006) 1.31
Effects of prayer and religious expression within computer support groups on women with breast cancer. Psychooncology (2007) 1.31
Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res (2003) 1.31
Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res (2006) 1.31
A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther (2006) 1.29
Evaluation of a hand-held, computer-based intervention to promote early self-care behaviors after lung transplant. Clin Transplant (2009) 1.24
Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem (2004) 1.24
Nonhistone Scm3 binds to AT-rich DNA to organize atypical centromeric nucleosome of budding yeast. Mol Cell (2011) 1.24
Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem (2008) 1.24
ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res (2007) 1.23
Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res (2002) 1.20
Cultural differences in use of an electronic discussion group. J Health Psychol (2003) 1.20
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem (2002) 1.20
Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia (2008) 1.20
HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci (2003) 1.20
The effects of combining Web-based eHealth with telephone nurse case management for pediatric asthma control: a randomized controlled trial. J Med Internet Res (2012) 1.19
Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther (2007) 1.18
Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer (2005) 1.18
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther (2010) 1.17
The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis (2002) 1.16
The value of theory for enhancing and understanding e-health interventions. Am J Prev Med (2010) 1.16
Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood (2003) 1.15
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res (2002) 1.14
DNA demethylation and cancer: therapeutic implications. Cancer Lett (2004) 1.11
Optimizing eHealth breast cancer interventions: which types of eHealth services are effective? Transl Behav Med (2011) 1.10
A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells. J Neuroinflammation (2009) 1.10
P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J Neurochem (2003) 1.07
High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J Neurochem (2002) 1.07
The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry (2009) 1.06
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.06
Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis (2005) 1.06
Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res (2012) 1.05
The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression. Cancer Cell Int (2006) 1.05
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res (2002) 1.05
Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis (2005) 1.05
Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs (2007) 1.05
Notch signaling through Jagged-1 is necessary to initiate chondrogenesis in human bone marrow stromal cells but must be switched off to complete chondrogenesis. Stem Cells (2008) 1.05
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer (2012) 1.04
An exploratory study of predictors of participation in a computer support group for women with breast cancer. Comput Inform Nurs (2006) 1.04
Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J (2005) 1.02
An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial. Cancer (2013) 1.02
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res (2005) 1.02
Green tea catechins as novel antitumor and antiangiogenic compounds. Curr Med Chem Anticancer Agents (2002) 1.01
Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res (2010) 1.01
Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol (2002) 1.01
Why do patients seek an alternative channel? The effects of unmet needs on patients' health-related Internet use. J Health Commun (2010) 1.00
A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer (2006) 1.00
Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype. Mol Cancer Res (2008) 0.99
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J (2003) 0.99
Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. Biochim Biophys Acta (2009) 0.99
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother (2009) 0.99
Inhibition of cancer cell proliferation and suppression of TNF-induced activation of NFkappaB by edible berry juice. Anticancer Res (2007) 0.99
Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun (2006) 0.98